Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raquelle I Mesholam-Gately

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Current Opinion in Psychiatry|March 12, 2025
Renaming schizophrenia: why, how, and what next?Raquelle I Mesholam-Gately, Arundati Nagendra, Matcheri Keshavan
Schizophrenia Research|April 2, 2014
Schizophrenia and co-occurring substance use disorder: reward, olfaction and clozapineRaquelle I Mesholam-Gately, Lauren E Gibson, Larry J Seidman, et al.
Psychiatry Research|June 5, 2019
Establishing a standard emotion processing battery for treatment evaluation in adults with autism spectrum disorder: Evidence supporting the Mayer-Salovey-Caruso Emotion Intelligence Test (MSCEIT)Susan S Kuo, Jessica A Wojtalik, Raquelle I Mesholam-Gately, et al.
Neuropsychology|May 6, 2009
Neurocognition in first-episode schizophrenia: a meta-analytic reviewRaquelle I Mesholam-Gately, Anthony J Giuliano, Kirsten P Goff, et al.
Psychological Medicine|July 13, 2019
Transdiagnostic validity of the MATRICS Consensus Cognitive Battery across the autism-schizophrenia spectrumSusan S Kuo, Jessica A Wojtalik, Raquelle I Mesholam-Gately, et al.
Psychiatry Research|April 30, 2013
Negative symptom improvement during cognitive rehabilitation: results from a 2-year trial of Cognitive Enhancement TherapyShaun M Eack, Raquelle I Mesholam-Gately, Deborah P Greenwald, et al.
Current Pharmaceutical Design|January 14, 2012
Neurocognition in the psychosis risk syndrome: a quantitative and qualitative reviewAnthony J Giuliano, Huijun Li, Raquelle I Mesholam-Gately, et al.
Journal of Psychiatric Research|May 31, 2022
Cognitive gains as a mechanism of functional capacity improvement in schizophrenia: Results from a multi-site randomized controlled trialAna T Flores, Susan S Hogarty, Raquelle I Mesholam-Gately, et al.
Psychiatry Research|June 2, 2023
Predictors of treatment discontinuation during an 18-month multi-site randomized trial of Cognitive Enhancement Therapy for early course schizophreniaJessica A Wojtalik, Wilson J Brown, Raquelle I Mesholam-Gately, et al.
Schizophrenia Research|December 31, 2025
Improving systems & communities of psychosis care: Proceedings from the 2024 Mass-STEP ConferenceIqra Imam, Kelsey A Johnson, Ananya Saluja, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Current Opinion in Psychiatry|March 12, 2025
Renaming schizophrenia: why, how, and what next?Raquelle I Mesholam-Gately, Arundati Nagendra, Matcheri Keshavan
Schizophrenia Research|April 2, 2014
Schizophrenia and co-occurring substance use disorder: reward, olfaction and clozapineRaquelle I Mesholam-Gately, Lauren E Gibson, Larry J Seidman, et al.
Psychiatry Research|June 5, 2019
Establishing a standard emotion processing battery for treatment evaluation in adults with autism spectrum disorder: Evidence supporting the Mayer-Salovey-Caruso Emotion Intelligence Test (MSCEIT)Susan S Kuo, Jessica A Wojtalik, Raquelle I Mesholam-Gately, et al.
Neuropsychology|May 6, 2009
Neurocognition in first-episode schizophrenia: a meta-analytic reviewRaquelle I Mesholam-Gately, Anthony J Giuliano, Kirsten P Goff, et al.
Psychological Medicine|July 13, 2019
Transdiagnostic validity of the MATRICS Consensus Cognitive Battery across the autism-schizophrenia spectrumSusan S Kuo, Jessica A Wojtalik, Raquelle I Mesholam-Gately, et al.
Psychiatry Research|April 30, 2013
Negative symptom improvement during cognitive rehabilitation: results from a 2-year trial of Cognitive Enhancement TherapyShaun M Eack, Raquelle I Mesholam-Gately, Deborah P Greenwald, et al.
Current Pharmaceutical Design|January 14, 2012
Neurocognition in the psychosis risk syndrome: a quantitative and qualitative reviewAnthony J Giuliano, Huijun Li, Raquelle I Mesholam-Gately, et al.
Journal of Psychiatric Research|May 31, 2022
Cognitive gains as a mechanism of functional capacity improvement in schizophrenia: Results from a multi-site randomized controlled trialAna T Flores, Susan S Hogarty, Raquelle I Mesholam-Gately, et al.
Psychiatry Research|June 2, 2023
Predictors of treatment discontinuation during an 18-month multi-site randomized trial of Cognitive Enhancement Therapy for early course schizophreniaJessica A Wojtalik, Wilson J Brown, Raquelle I Mesholam-Gately, et al.
Schizophrenia Research|December 31, 2025
Improving systems & communities of psychosis care: Proceedings from the 2024 Mass-STEP ConferenceIqra Imam, Kelsey A Johnson, Ananya Saluja, et al.
Pageof 6